CALA

Calithera Biosciences, Inc.
CAPPED RATING

Calithera Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

Calithera Biosciences, Inc. (CALA) is rated C (2.3/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (D). The rating has held at C for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
D
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 0.0%
Price Return 12M 200.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -15.0%

Historical Factor Score Progression

Held C for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2021-09-30 C+ (2.5) C+ (2.5) D+ (1.8) B (3.3) D (1.5) C (2.3)
2021-06-30 C+ (2.5) C+ (2.5) D+ (1.8) B (3.3) D (1.5) C (2.3)